William Blair Investment Management LLC boosted its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 4.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 337,035 shares of the biopharmaceutical company’s stock after buying an additional 12,912 shares during the period. William Blair Investment Management LLC owned 1.45% of Madrigal Pharmaceuticals worth $169,852,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MDGL. Persistent Asset Partners Ltd acquired a new position in shares of Madrigal Pharmaceuticals during the 2nd quarter valued at about $29,000. Global Retirement Partners LLC purchased a new position in shares of Madrigal Pharmaceuticals during the 2nd quarter worth about $34,000. Jacobi Capital Management LLC acquired a new stake in shares of Madrigal Pharmaceuticals in the third quarter worth approximately $54,000. Provenance Wealth Advisors LLC acquired a new stake in shares of Madrigal Pharmaceuticals in the third quarter worth approximately $69,000. Finally, Root Financial Partners LLC purchased a new stake in Madrigal Pharmaceuticals in the third quarter valued at approximately $82,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.
Madrigal Pharmaceuticals Price Performance
Madrigal Pharmaceuticals stock opened at $427.39 on Monday. Madrigal Pharmaceuticals, Inc. has a 52-week low of $353.54 and a 52-week high of $615.00. The firm has a fifty day moving average of $475.72 and a 200-day moving average of $495.79. The firm has a market capitalization of $9.93 billion, a P/E ratio of -71.47 and a beta of -0.98. The company has a quick ratio of 2.78, a current ratio of 3.05 and a debt-to-equity ratio of 0.54.
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share for the quarter, beating the consensus estimate of ($1.09) by $2.92. The business had revenue of $431.27 million for the quarter, compared to analyst estimates of $404.17 million. Madrigal Pharmaceuticals had a negative net margin of 10.89% and a negative return on equity of 27.08%. During the same quarter in the previous year, the business posted ($5.08) EPS. As a group, analysts predict that Madrigal Pharmaceuticals, Inc. will post -2.08 EPS for the current year.
Insider Activity at Madrigal Pharmaceuticals
In related news, General Counsel Shannon Kelley sold 1,077 shares of the stock in a transaction on Friday, November 6th. The stock was sold at an average price of $400.00, for a total value of $430,800.00. Following the completion of the sale, the general counsel directly owned 10,397 shares in the company, valued at approximately $4,158,800. This represents a 9.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bros. Advisors Lp Baker acquired 76,140 shares of the business’s stock in a transaction on Friday, November 6th. The stock was bought at an average cost of $384.32 per share, for a total transaction of $29,262,124.80. Following the completion of the transaction, the director directly owned 2,040,682 shares of the company’s stock, valued at $784,274,906.24. This trade represents a 3.88% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders sold 12,660 shares of company stock worth $6,670,042. Corporate insiders own 17.60% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities analysts recently commented on MDGL shares. UBS Group reaffirmed a “buy” rating and set a $735.00 price target on shares of Madrigal Pharmaceuticals in a research report on Wednesday, October 14th. Barclays decreased their price target on shares of Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating on the stock in a report on Monday, August 3rd. Wolfe Research upgraded shares of Madrigal Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $605.00 price target on the stock in a report on Tuesday, August 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research note on Thursday, October 15th. Finally, Wells Fargo & Company began coverage on Madrigal Pharmaceuticals in a report on Monday, July 27th. They set an “overweight” rating and a $685.00 price objective for the company. Fourteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $706.87.
View Our Latest Analysis on MDGL
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The company is headquartered in Conshohocken, Pennsylvania. Its lead product, Rezdiffra (resmetirom), is a thyroid hormone receptor-beta agonist. The U.S. Food and Drug Administration approved Rezdiffra in 2024 for use with diet and exercise in adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis.
See Also
- Five stocks we like better than Madrigal Pharmaceuticals
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
